The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca PLC AZN shares inched down 0.09% to £111.70 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.35% to 8,533.87 ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

The mega investment is in line with Astrazeneca’s global ambition to achieve 80 billion dollars in Total Revenue and to bring ...

One of these companies' quantum platforms can complete calculations in minutes that would take today's supercomputers longer ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...